We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

74 hedge funds and large institutions have $113M invested in Invesco Biotechnology & Genome ETF in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

1% more funds holding

Funds holding: 73 → 74 (+1)

10% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 21

1.52% less ownership

Funds ownership: 31.08% → 29.56% (-1.5%)

12% less capital invested

Capital invested by funds: $129M → $113M (-$16.2M)

Holders
74
Holders Change
+1
Holders Change %
+1.37%
% of All Funds
2.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
19
Reduced
21
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$2.87M
2
Morgan Stanley
Morgan Stanley
New York
+$2.26M
3
CLOS
Compagnie Lombard Odier SCmA
Switzerland
+$1M
4
HBT
Hills Bank & Trust
Iowa
+$802K
5
Neuberger Berman Group
Neuberger Berman Group
New York
+$337K

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$4.3M
2
NCM
Niemann Capital Management
Nevada
-$4.09M
3
Jane Street
Jane Street
New York
-$3.96M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.17M
5
U
UBS
Switzerland
-$3.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$544K +$7.54K +186 +2%
BPC
27
Banque Pictet & Cie
Switzerland
$515K – – –
MAA
28
Managed Account Advisors
New Jersey
$460K +$162K +4,006 +61%
Janney Montgomery Scott
29
Janney Montgomery Scott
Pennsylvania
$436K +$4.25K +105 +1%
Citigroup
30
Citigroup
New York
$366K +$56.7K +1,399 +20%
Neuberger Berman Group
31
Neuberger Berman Group
New York
$364K +$337K +8,325 New
ONB
32
Old National Bancorp
Indiana
$356K +$330K +8,142 New
IAA
33
Ironsides Asset Advisors
North Carolina
$348K +$323K +7,964 New
OIA
34
Optimum Investment Advisors
Illinois
$328K +$25.5K +630 +9%
CAN
35
Cetera Advisor Networks
California
$327K -$7.94K -196 -3%
Verition Fund Management
36
Verition Fund Management
Connecticut
$301K -$597K -14,744 -68%
JIC
37
Joel Isaacson & Co
New York
$301K – – –
OC
38
Oppenheimer & Co
New York
$298K +$40.3K +995 +17%
PJSIMP
39
P.J. Schmidt Investment Management (PJS)
Wisconsin
$292K -$10.1K -250 -4%
CIC
40
Carnegie Investment Counsel
Ohio
$278K -$18.2K -450 -7%
NPC
41
National Planning Corporation
California
$266K +$10.7K +263 +5%
B
42
Baird
Wisconsin
$258K +$239K +5,910 New
LTFS
43
Ladenburg Thalmann Financial Services
Florida
$255K -$310K -7,647 -57%
Jane Street
44
Jane Street
New York
$237K -$3.96M -97,653 -95%
WA
45
WBH Advisory
Maryland
$225K +$122 +3 +0.1%
MC
46
Moors & Cabot
Massachusetts
$219K +$203K +5,014 New
WEC
47
Winslow Evans & Crocker
Massachusetts
$141K – – –
SG Americas Securities
48
SG Americas Securities
New York
$119K +$110K +2,723 New
WA
49
WFG Advisors
Texas
$114K -$1.17M -28,997 -92%
MFS
50
MSI Financial Services
Massachusetts
$106K +$70.9K +1,750 +261%
1
2
3 4

PBE Hedge Fund Activity: Q2 2014 in Review

74 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2014, worth a combined $113M — down 12% from $129M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PBE positions and 10 closed out — a net gain of 3 holders — while 19 added to existing stakes and 21 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $2.87M. The largest seller was Wells Fargo, cutting an estimated $4.3M.

  • 74 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2014, up from 73 in Q1 2014.
  • Funds reported $113M of Invesco Biotechnology & Genome ETF stock for Q2 2014, down 12% quarter-over-quarter.
  • 13 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2014 and 10 closed out, a net change of +3 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q2 2014 was Goldman Sachs, an estimated $2.87M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q2 2014 was Wells Fargo, an estimated $4.3M sold.

Based on aggregated 13F filings for Q2 2014.